Does early postsurgical temozolomide plus concomitant radiochemotherapy regimen have any benefit in newly-diagnosed glioblastoma patients? A multi-center, randomized, parallel, open-label, phase II clinical trial

Chinese Medical Journal

Volumn 128, Issue 20, 2015, Pages 2751-2758

  Mao, Ying ^a   Yao, Yu ^a   Zhang, Li Wei ^b   Lu, Yi Cheng ^c   Chen, Zhong Ping ^d   Zhang, Jian Min ^e   Qi, Song Tao ^f   You, Chao ^g   Wang, Ren Zhi ^h   Yang, Shu Yuan ⁱ   Zhang, Xiang ^j   Wang, Ji Sheng ^b   Chen, Ju Xiang ^c   Yang, Qun Ying ^d   Shen, Hong ^e   Li, Zhi Yong ^f   Wang, Xiang ^g   Ma, Wen Bin ^h   Yang, Xue Jun ⁱ   Zhen, Hai Ning ^j   Zhou, Liang Fu ^a   more..

^a FUDAN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f SOUTHERN MEDICAL UNIVERSITY   (China)

^g SICHUAN UNIVERSITY   (China)

^h PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

ⁱ TIANJIN MEDICAL UNIVERSITY   (China)

^j FOURTH MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

Chemoradiotherapy; Chemotherapy; Glioblastoma; Malignant Glioma; Temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLORIDE; GLUCOSE; POTASSIUM; PROTEIN; SODIUM; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMORADIOTHERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944474459     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.167313     Document Type: Article

References (23)

1. Kotliarova S, Fine HA. Snapshot: Glioblastoma multiforme. Cancer Cell 2012;21:710-710.e1.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Welch M, Lai R. Glioblastoma multiforme. Curr Treat Options Neurol 2009;11:297-305.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
6. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91.
7. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
8. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2009;11:842-52.
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
10. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002;64:259-73.
11. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-60.
12. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70:217-28.
13. Nduom EK, Hadjipanayis CG, Van Meir EG. Glioblastoma cancer stem-like cells: Implications for pathogenesis and treatment. Cancer J 2012;18:100-6.
14. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
15. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008;68:5706-15.
16. Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010;12:756-60.
17. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11.
18. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009;27:3861-7.
19. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013;15:242-50.
20. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
21. d’Avella D, DellaPuppa A. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas. Acta Neurochir (Wien) 2012;154:1379-81.
22. Price SJ, Whittle IR, Ashkan K, Grundy P, Cruickshank G; UK-HGG Study Group. NICE guidance on the use of carmustine wafers in high grade gliomas: A national study on variation in practice. Br J Neurosurg 2012;26:331-5.
23. Villano JL, Letarte N, Yu JM, Abdur S, Bressler L. Hematologic adverse events associated with temozolomide. Cancer Ther Pharmacol 2011;69:107-13.